Fly-E Group, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Fly-E Group, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $25.43M | Jul 15, 2025 |
| FY2025 | Mar 31, 2024 | $32.21M | Jul 15, 2025 |
| FY2024 | Mar 31, 2023 | $21.77M | Jun 28, 2024 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $10.45M | Jul 15, 2025 |
| FY2025 | Mar 31, 2024 | $13.11M | Jul 15, 2025 |
| FY2024 | Mar 31, 2023 | $8.29M | Jun 28, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($5.29M) | Jul 15, 2025 |
| FY2025 | Mar 31, 2024 | $1.90M | Jul 15, 2025 |
| FY2024 | Mar 31, 2023 | $1.38M | Jun 28, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($4.56M) | Jul 15, 2025 |
| FY2025 | Mar 31, 2024 | $3.26M | Jul 15, 2025 |
| FY2024 | Mar 31, 2023 | $2.31M | Jun 28, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $549.4K | Jul 15, 2025 |
| FY2025 | Mar 31, 2024 | $292.7K | Jul 15, 2025 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($10.06M) | Jul 15, 2025 |
| FY2025 | Mar 31, 2024 | $4.31M | Jul 15, 2025 |
| FY2024 | Mar 31, 2023 | $1.76M | Jun 28, 2024 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $1.63M | Jul 15, 2025 |
| FY2025 | Mar 31, 2024 | $1.25M | Jul 15, 2025 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $33.71M | Jul 15, 2025 |
| FY2025 | Mar 31, 2024 | $28.98M | Jul 15, 2025 |
| FY2024 | Mar 31, 2023 | $17.26M | Jun 28, 2024 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $23.87M | Jul 15, 2025 |
| FY2025 | Mar 31, 2024 | $22.19M | Jul 15, 2025 |
| FY2024 | Mar 31, 2023 | $14.76M | Jun 28, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $9.83M | Jul 15, 2025 |
| FY2025 | Mar 31, 2024 | $6.78M | Jul 15, 2025 |
| FY2025 | Mar 31, 2023 | $2.50M | Jul 15, 2025 |
| FY2024 | Mar 31, 2022 | $1.12M | Jun 28, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($895.5K) | Jul 15, 2025 |
| FY2025 | Mar 31, 2024 | $4.40M | Jul 15, 2025 |
| FY2024 | Mar 31, 2023 | $2.50M | Jun 28, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $840.1K | Jul 15, 2025 |
| FY2025 | Mar 31, 2024 | $1.40M | Jul 15, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | (1) | Jul 15, 2025 |
| FY2025 | Mar 31, 2024 | 0 | Jul 15, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Jun 28, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 4.92M | Jul 15, 2025 |
| FY2025 | Mar 31, 2024 | 4.40M | Jul 15, 2025 |
| FY2024 | Mar 31, 2023 | 22.00M | Jun 28, 2024 |